Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease

SPECT Scan
dopamine transporter
dopamine
  • 0 views
  • 23 Mar, 2022
  • 1 location
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

This phase II trial studies how well ABL001 works in treating patients with chronic myeloid leukemia who are on therapy with tyrosine kinase inhibitor. ABL001 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ABL001 and tyrosine kinase inhibitor together may …

  • 0 views
  • 23 Mar, 2022
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.

remission
philadelphia chromosome
leukemia
tyrosine
dasatinib
  • 2 views
  • 25 Mar, 2022
  • 3 locations
Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

a new therapeutic goal for chronic myeloid leukemia in chronic phase (CML-CP). In ENESTnd and DASISION trials, both nilotinib and dasatinib achieved DMR more effectively than imatinib. In the

  • 0 views
  • 15 Feb, 2021
  • 1 location
Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia

patients who has poor response or intolerance for TKI drugs( Imatinib, dasatinib, nilotinib). Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib,and it aslo

Accepts healthy volunteers
  • 0 views
  • 20 Apr, 2022
  • 1 location
A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML

patients with Ph+ CML-CP who have been treated with second-generation TKIs (nilotinib, dasatinib) for at least 3 years and maintains MMR for at least 2 years, continue to be treated with halved

  • 0 views
  • 29 Apr, 2022
  • 1 location
Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

The GIMEMA CML Working Party promotes an observational (retrospective and perspective) study of Imatinib-resistant or intolerant CML patients treated with Nilotinib in Italy. Enrollment will

dasatinib
imatinib
leukemia
nilotinib
  • 12 views
  • 25 Mar, 2022
  • 31 locations
Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning Failure) to Imatinib or Dasatinib

more likely to obtain clinical efficacy by switching to the second-generation TKI nilotinib; patients with Y253H, E255K/V and F359C/V/I mutations are more likely to obtain clinical efficacy by

  • 2 views
  • 11 Jun, 2021
  • 1 location
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study (TIKlet)

Rationale The pharmacokinetics of imatinib and nilotinib, two BCR/Abl tyrosine-kinase inhibitors (TKI), is variable among patients suffering from chronic myeloid leukemia (CML

tyrosine
leukemia
imatinib
nilotinib
bcr-abl protein
  • 0 views
  • 24 Mar, 2022
A Study for Tyrosine Kinase Inhibitors Discontinuation

the BCR-ABL kinase are currently on the market in France, nilotinib (Tasigna, Novartis Laboratories) in the first and second-line treatment and dasatinib (SPRYCEL, Bristol-Myers Squibb Laboratories

remission
imatinib
myeloid leukemia
nilotinib
chronic myeloid leukemia
  • 0 views
  • 22 Jan, 2021
  • 1 location